Immunology and inflammation

News

Biogen bets $1.15bn on immunology drug developer HI-Bio

Biogen has expanded its specialty immunology pipeline with an agreement to buy Human Immunology Biosciences (HI-Bio) and its lead drug felzartamab, in trials for a range o

News

Immune checkpoint enhancer biotech AltruBio raises $225m

A healthy run of nine-figure private rounds for biotechs in the US has continued with an impressive $225 million Series B for immunotherapy specialist AltruBio.

News

MS and fibrosis drug developer Contineum files $150m IPO

Contineum Therapeutics has become the latest biotech to file for an initial public offering (IPO) in the US, hoping to raise $150 million for its early clinical-stage cand

News

AAD: Sanofi showcases data on possible Dupixent successor

Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD) after reporting new phase 2

News

AbbVie inks $713m deal for OSE chronic inflammation drug

AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Im

News

FDA changes its mind and approves Takeda’s Eohilia

In its second attempt, Takeda has secured FDA approval for Eohilia, which becomes the first and only oral therapy in the US for eosinophilic oesophagitis (EoE).

Biogen bets $1.15bn on immunology drug developer HI-Bio

Immune checkpoint enhancer biotech AltruBio raises $225m

MS and fibrosis drug developer Contineum files $150m IPO

AAD: Sanofi showcases data on possible Dupixent successor

AbbVie inks $713m deal for OSE chronic inflammation drug

FDA changes its mind and approves Takeda’s Eohilia

NHS use of digital cardiac rehab tools endorsed

How to meet your physicians where they are online

Immunology and inflammation

Editor's Picks